MEF2D and acute lymphoblastic leukemia: In contrast to KMT2A-rearranged B-ALL, differences between ELP signals and later B-cell signals were significant in PAX5- and MEF2D-mutated B-ALL (P < 0.01 and P < 0.05, respectively; Wilcoxon signed-rank test).